Skip to main content
Top
Published in: Endocrine Pathology 2/2008

01-06-2008

Galectin-3 Expression in Tumor Progression and Metastasis of Papillary Thyroid Carcinoma

Authors: Hüseyin K. Türköz, Hülya Öksüz, Ziya Yurdakul, Deniz Özcan

Published in: Endocrine Pathology | Issue 2/2008

Login to get access

Abstract

Galectin-3 plays important roles in cell adhesion, cell proliferation, apoptosis, neoplastic transformation, and metastasis. Galectin-3 expression has been evaluated in various malignant neoplasms to determine its effectiveness in differential diagnosis from benign lesions and its effects on carcinogenesis. There are few and somewhat controversial results regarding its changes through cancer progression in thyroid malignancies. We studied the presence of galectin-3 expression immunohistochemically and its relation with tumor invasiveness and lymph node metastasis in 89 cases of papillary carcinoma of the thyroid. Galectin overexpression was less frequent in cases with lymph node metastases compared with cases without lymph node metastasis (P = 0.001). Metastatic foci in lymph nodes showed a lower degree of galectin-3 overexpression than their primary lesions (P = 0.001). Degree of galectin-3 overexpression was also lower in larger tumors (P = 0.009). Additionally, a decreased level of galectin-3 overexpression was observed at the invasive edges of the tumors (P = 0.001). Galectin-3 overexpression is more profound in early stages of papillary carcinoma, and its expression intensity decreases during tumor progression. This finding is consistent with roles for galectin-3 in cell adhesion to other tumor cells and the matrix.
Literature
1.
go back to reference Wang JL, Werner EA, Laing JG, Patterson RJ. Nuclear and cytoplasmic localization of a lectin–ribonucleoprotein complex. Biochem Soc Trans 20(2):269–74, 1992.PubMed Wang JL, Werner EA, Laing JG, Patterson RJ. Nuclear and cytoplasmic localization of a lectin–ribonucleoprotein complex. Biochem Soc Trans 20(2):269–74, 1992.PubMed
2.
go back to reference Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell–cell adhesion. Cancer Res 56(19):4530–4, 1996.PubMed Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell–cell adhesion. Cancer Res 56(19):4530–4, 1996.PubMed
5.
go back to reference Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18(4):787–92, 2001.PubMed Yoshii T, Inohara H, Takenaka Y, Honjo Y, Akahani S, Nomura T, et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int J Oncol 18(4):787–92, 2001.PubMed
6.
go back to reference Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15(1):143–8, 1999.PubMed Nakamura M, Inufusa H, Adachi T, Aga M, Kurimoto M, Nakatani Y, et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 15(1):143–8, 1999.PubMed
7.
go back to reference Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 9(2):305–28, 2004.PubMed Krzeslak A, Lipinska A. Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 9(2):305–28, 2004.PubMed
8.
go back to reference Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005. doi:10.1038/modpathol.3800235.PubMedCrossRef Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005. doi:10.​1038/​modpathol.​3800235.PubMedCrossRef
10.
go back to reference DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. Lyon: IARC, pp. 50–66, 2004. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. Lyon: IARC, pp. 50–66, 2004.
11.
go back to reference Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58(14):3015–20, 1998.PubMed Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 58(14):3015–20, 1998.PubMed
12.
go back to reference Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, Chapelle Ade L, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005. doi:10.1038/modpathol.3800235.PubMedCrossRef Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, Chapelle Ade L, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18(1):48–57, 2005. doi:10.​1038/​modpathol.​3800235.PubMedCrossRef
13.
go back to reference Torres-Cabala C, Bibbo M, Panizo-Santos A, Barazi H, Krutzsch H, Roberts DD, et al. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 50(5):518–28, 2006.PubMed Torres-Cabala C, Bibbo M, Panizo-Santos A, Barazi H, Krutzsch H, Roberts DD, et al. Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 50(5):518–28, 2006.PubMed
14.
go back to reference Rossi ED, Raffaelli M, Mule’ A, Miraglia A, Lombardi CP, Vecchio FM, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Acta Cytol 50(5):518–28, 2006. Rossi ED, Raffaelli M, Mule’ A, Miraglia A, Lombardi CP, Vecchio FM, et al. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Acta Cytol 50(5):518–28, 2006.
15.
go back to reference Castronovo V, Campo E, van den Brule FA, Claysmith AP, Cioce V, Liu FT, et al. Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 84(15):1161–9, 1992. doi:10.1093/jnci/84.15.1161.PubMedCrossRef Castronovo V, Campo E, van den Brule FA, Claysmith AP, Cioce V, Liu FT, et al. Inverse modulation of steady-state messenger RNA levels of two non-integrin laminin-binding proteins in human colon carcinoma. J Natl Cancer Inst 84(15):1161–9, 1992. doi:10.​1093/​jnci/​84.​15.​1161.PubMedCrossRef
17.
go back to reference Idikio H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12(6):1287–90, 1998.PubMed Idikio H. Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12(6):1287–90, 1998.PubMed
19.
20.
go back to reference Song YK, Billiar TR, Lee YJ. Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 160(3):1069–75, 2002.PubMed Song YK, Billiar TR, Lee YJ. Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 160(3):1069–75, 2002.PubMed
21.
go back to reference Aratake Y, Nomura H, Kotani T, Marutsuka K, Kobayashi K, Kuma K, et al. Coexistent anaplastic and differentiated thyroid carcinoma. Am J Clin Pathol 125(3):399–406, 2006. doi:10.1309/LF3Q-1NQK-MT2N-9KNV. Aratake Y, Nomura H, Kotani T, Marutsuka K, Kobayashi K, Kuma K, et al. Coexistent anaplastic and differentiated thyroid carcinoma. Am J Clin Pathol 125(3):399–406, 2006. doi:10.​1309/​LF3Q-1NQK-MT2N-9KNV.
22.
go back to reference Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31(4):428–33, 2000. doi:10.1053/hp.2000.6534.PubMedCrossRef Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31(4):428–33, 2000. doi:10.​1053/​hp.​2000.​6534.PubMedCrossRef
23.
go back to reference Cvejic DS, Savin SB, Petrovic IM, Paunovic IR, Tatic SB, Havelka MJ. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. Head Neck 27(12):1049–55, 2005. doi:10.1002/hed.20276.PubMedCrossRef Cvejic DS, Savin SB, Petrovic IM, Paunovic IR, Tatic SB, Havelka MJ. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size. Head Neck 27(12):1049–55, 2005. doi:10.​1002/​hed.​20276.PubMedCrossRef
Metadata
Title
Galectin-3 Expression in Tumor Progression and Metastasis of Papillary Thyroid Carcinoma
Authors
Hüseyin K. Türköz
Hülya Öksüz
Ziya Yurdakul
Deniz Özcan
Publication date
01-06-2008
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 2/2008
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-008-9033-3

Other articles of this Issue 2/2008

Endocrine Pathology 2/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.